IPO Timeline Raw facts
Company Overview
| Stock Name | Pegbio Co-B |
|---|---|
| Stock Code | 02565 |
| Company Full Name | PegBio Co., Ltd. |
| Industry | 醫療保健 |
| Principal Activities | 公司成立于2008年,是一家專注于自主研究及開發慢性病創新療法的生物技術公司,重點關注內分泌代謝領域。 |
| Listing Date | 2025-05-27 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市拱墅區皓章大廈1幢606室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.pegbio.com/ |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 15.60 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 7,800 |
| Par Value | To be extracted |
| Offer Period | 2025-05-19 to 2025-05-22 |
| Global Offering Shares | 19,283,500 shares |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 49.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 300,822,600 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 7,800 |
| 2 lots | 1,000 | HK$ 15,600 |
| 3 lots | 1,500 | HK$ 23,400 |
| 4 lots | 2,000 | HK$ 31,200 |
| 5 lots | 2,500 | HK$ 39,000 |
| 6 lots | 3,000 | HK$ 46,800 |
| 7 lots | 3,500 | HK$ 54,600 |
| 8 lots | 4,000 | HK$ 62,400 |
| 9 lots | 4,500 | HK$ 70,200 |
| 10 lots | 5,000 | HK$ 78,000 |
| 12 lots | 6,000 | HK$ 93,600 |
| 14 lots | 7,000 | HK$ 109,200 |
| 16 lots | 8,000 | HK$ 124,800 |
| 18 lots | 9,000 | HK$ 140,400 |
| 20 lots | 10,000 | HK$ 156,000 |
| 30 lots | 15,000 | HK$ 234,000 |
| 40 lots | 20,000 | HK$ 312,000 |
| 50 lots | 25,000 | HK$ 390,000 |
| 60 lots | 30,000 | HK$ 468,000 |
| 70 lots | 35,000 | HK$ 546,000 |
| 80 lots | 40,000 | HK$ 624,000 |
| 90 lots | 45,000 | HK$ 702,000 |
| 100 lots | 50,000 | HK$ 780,000 |
| 120 lots | 60,000 | HK$ 936,000 |
| 140 lots | 70,000 | HK$ 1,092,000 |
| 160 lots | 80,000 | HK$ 1,248,000 |
| 180 lots | 90,000 | HK$ 1,404,000 |
| 200 lots | 100,000 | HK$ 1,560,000 |
| 300 lots | 150,000 | HK$ 2,340,000 |
| 400 lots | 200,000 | HK$ 3,120,000 |
| 500 lots | 250,000 | HK$ 3,900,000 |
| 600 lots | 300,000 | HK$ 4,680,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 700 lots | 350,000 | HK$ 5,460,000 |
| 800 lots | 400,000 | HK$ 6,240,000 |
| 900 lots | 450,000 | HK$ 7,020,000 |
| 1,000 lots | 500,000 | HK$ 7,800,000 |
| 1,100 lots | 550,000 | HK$ 8,580,000 |
| 1,200 lots | 600,000 | HK$ 9,360,000 |
| 1,300 lots | 650,000 | HK$ 10,140,000 |
| 1,400 lots | 700,000 | HK$ 10,920,000 |
| 1,500 lots | 750,000 | HK$ 11,700,000 |
| 1,600 lots | 800,000 | HK$ 12,480,000 |
| 1,700 lots | 850,000 | HK$ 13,260,000 |
| 1,928 lots | 964,000 | HK$ 15,038,400 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 9.35B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | RMB 28.39 million |
| Listing Expenses | ~HK$ 69,100,000 |
| Listing Expenses / Funds Raised | ~23.0% |
| Total Pre-IPO Investment | approximately USD 50.3 million |
| First Day Close | HK$ 11.56 |
|---|---|
| First Day Open | HK$ 13.0 |
| First Day Change | -25.90% |
| First Day Volume | 11264800.0 |
| First Day Turnover | 150891000.0 |
| Use of Proceeds | 1、約116.5百萬港元(或約50.2%)用于撥付核心產品PB-119的商業化及適應癥擴展;
2、約79.9百萬港元(或約34.5%)用于撥付主要產品PB-718的進一步開發;
3、約12.2百萬港元(或約5.3%)用于撥付其他管線候選產品正在進行及計劃進行的研發;
4、約2.3百萬港元(或約1.0%)將用于業務開發活動及加強海外業務;
5、約20.9百萬港元(或約9.0%)將用作營運資金及其他一般公司用途。 |
Underwriting Syndicate
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 益泽康瑞医药(香港)有限公司 | 149,518,200 HKD | — | 49.70% | — | 6 months | 2025-11-27 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Michael Min XU | — |
| Company Secretary | 黃一峰,郭恩廷 | — |
Major Shareholders
| Major Shareholders & Holdings | Michael Min XU(15.05%),Mingly China Growth Fund, L.P.(9.03%),上海蘇頡企業管理咨詢合伙企業(有限合伙)(7.56%),元生創投(5.26%) |
|---|
Market Sentiment
The IPO was met with overwhelming demand, achieving an oversubscription ratio of 743.78x. The hit rate of just 20.95% underscores intense competition for allocations. Clawback C triggered significant reallocation to the public tranche, reflecting strong retail interest. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
Tier distribution data is not provided, precluding analysis of allocation anomalies or broker fee efficiency. Without detailed subscription figures by tier, no pattern can be observed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Demographic breakdowns are entirely missing from the dataset, with holder counts and regional percentages set to zero. It is unclear whether mainland or local participation drove the demand. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)




